Mr Moulton and GM&C Life Sciences Fund join £4.3m funding round
Infex Therapeutics has secured £4.3m in funding(Image: Infex Therapeutics)
Venture capitalist Jon Moulton has backed a biotech firm that’s looking to tackle the “critical global threat” of infections that are resistant to antibiotics.
Infex Therapeutics, of Alderley Edge, has secured £4.3m in a funding round led by Mr Moulton alongside the GM&C Life Sciences Fund, managed by Catapult Ventures, and existing high net worth investors.
The company will use the funding to develop its pipeline of new anti-infectives targeting antimicrobial resistance (AMR) and other “critical-priority infectious diseases”.
Dr Peter Jackson, CEO of Infex Therapeutics, said: “We are delighted to secure this investment led by Jon Moulton, with support from the Greater Manchester and Cheshire Lifescience Investment Fund and our existing investors.
“This funding represents strong validation of our progress in developing novel anti-infectives to address the critical global threat of antimicrobial resistance.”
Jon Moulton, founder of Better Capital and now chair of Infex Therapeutics, said: “We have supported Infex from the beginning and continue to be impressed by the company’s scientific progress and strategic execution.”
He highlighted Infex’s lead programme RESP-X, which is being trialled as a therapy for non-cystic fibrosis bronchiectasis (NCFB) patients.
And he said: ”This additional investment reflects our strong conviction in both the team and its innovative approach to tackling antimicrobial resistance.
Nick Wright, CEO of Catapult Ventures which manages the GM&C Life Sciences Fund, said: “Infex Therapeutics has made excellent scientific progress since we first invested several years ago. The company has clearly established itself as a world leader in the AMR and related space and the data it is generating is very compelling.”
You must be logged in to post a comment Login